Merck & Company, Inc. (MRK) Holdings Maintained by Eos Management L.P.

Eos Management L.P. maintained its position in shares of Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to the company in its most recent filing with the SEC. The firm owned 6,979 shares of the company’s stock at the close of the second quarter. Merck & accounts for 0.3% of Eos Management L.P.’s portfolio, making the stock its 19th biggest position. Eos Management L.P.’s holdings in Merck & were worth $443,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. RB Capital Management LLC increased its holdings in shares of Merck & by 0.5% during the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after purchasing an additional 23 shares during the period. Baystate Wealth Management LLC increased its holdings in shares of Merck & by 0.4% during the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after purchasing an additional 27 shares during the period. Bath Savings Trust Co increased its holdings in shares of Merck & by 0.5% during the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after purchasing an additional 28 shares during the period. Camelot Portfolios LLC increased its holdings in shares of Merck & by 0.4% during the 1st quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after purchasing an additional 33 shares during the period. Finally, Stillwater Investment Management LLC increased its holdings in shares of Merck & by 0.8% during the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock worth $296,000 after purchasing an additional 38 shares during the period. Institutional investors own 73.15% of the company’s stock.

Several research analysts have recently issued reports on MRK shares. UBS AG boosted their price objective on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies set a $70.00 price objective on shares of Merck & and gave the stock a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets restated a “buy” rating and set a $72.00 price objective on shares of Merck & in a report on Friday, September 8th. Citigroup Inc. upgraded shares of Merck & from a “neutral” rating to a “buy” rating and set a $72.00 price objective on the stock in a report on Wednesday, October 18th. Finally, J P Morgan Chase & Co set a $70.00 price objective on shares of Merck & and gave the stock a “buy” rating in a report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $67.07.

Shares of Merck & Company, Inc. (MRK) opened at $54.99 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market cap of $150,116.47, a PE ratio of 14.16, a price-to-earnings-growth ratio of 2.37 and a beta of 0.78. Merck & Company, Inc. has a 52 week low of $54.41 and a 52 week high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 earnings per share. sell-side analysts predict that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Merck & Company, Inc. (MRK) Holdings Maintained by Eos Management L.P.” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/15/merck-company-inc-mrk-holdings-maintained-by-eos-management-l-p.html.

In other news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

Merck & Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply